NCT03872778 - [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 24, 2019

Primary Completion Date

November 24, 2025

Study Completion Date

December 1, 2026

Conditions

Neoplasms

Interventions

DRUG

[177Lu]-NeoB

\[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion

DRUG

[68Ga]-NeoB

\[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation

DRUG

LCZ696

dose strength 49/51 mg, film-coated tablets for oral use

Trial Locations (11)

Pittsburgh University, Pittsburgh

John Hopkins University, Baltimore

MD Anderson Cancer Center, Houston

City of Hope, Duarte

Stanford University, Stanford

Oregon Health & Science University, Portland

Medical University of Innsbruck, Innsbruck

CHU de Grenoble, La Tronche

Erasmus MC, Rotterdam

Vall d'Hebron Institute of Oncology, Barcelona

Addenbroke's hospital, Cambridge